From Financial Modeling Prep: 2025-03-07 07:00:07

Neuronetics, Inc. (NASDAQ:STIM) develops non-invasive treatments for psychiatric disorders, notably major depressive disorder, through its NeuroStar Advanced Therapy System. Facing competition from Kezar Life Sciences, Scholar Rock Holding Corporation, Verrica Pharmaceuticals, SI-BONE, and Sutro Biopharma. Neuronetics reports a ROIC of -32.27%, underperforming its WACC of 12.03%, indicating inefficiency in generating returns. Comparatively, Kezar Life Sciences shows even lower efficiency with a ROIC of -64.27% and a WACC of 6.37. Scholar Rock Holding Corporation and Verrica Pharmaceuticals also exhibit lower efficiency with ROIC to WACC ratios of -8.56 and -55.95, respectively. SI-BONE, Inc. performs slightly better with a ROIC of -17.82% and a WACC of 10.01%, resulting in a ROIC to WACC ratio of -1.78. Sutro Biopharma is the least inefficient among the peers with a ROIC to WACC ratio of -1.64. Neuronetics, although not currently generating positive returns, is relatively more efficient than some competitors in the medical technology and biopharmaceutical sectors.



Read more at Financial Modeling Prep:: Neuronetics, Inc. (NASDAQ:STIM) Financial Efficien…